Literature DB >> 6247869

Plasma 11-deoxycortisol, androstenedione, testosterone and ACTH in comparison with the urinary excretion of tetrahydro-11-deoxycortisol as indices of the pituitary-adrenal response to oral metyrapone.

W E de Lange, W J Sluiter, J J Pratt, H Doorenbos.   

Abstract

Plasma levels of ACTH, 11-deoxycortisol, androstenedione and testosterone and urinary tetrahydro-11-deoxycortisol were determined during a two day oral metyrapone test using doses of 1.5 g every 6 h. The level of 11-deosycortisol 48 h after the start was distinctive regarding the assessment of pituitary ACTH secretory capacity. The rise of androstenedione concentration after 48 h is distinctive in a similar way, whereas ACTH determination is of little diagnostic value in this respect. Further, an increase in testosterone level can be observed in cases of low basal testosterone production. This increase is probably the result of peripheral conversion of androstenedione to testosterone. Where the basal testosterone concentration was high, no change could be measured.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6247869     DOI: 10.1530/acta.0.0930488

Source DB:  PubMed          Journal:  Acta Endocrinol (Copenh)        ISSN: 0001-5598


  3 in total

Review 1.  Cushing's syndrome in children and adolescents: current diagnostic and therapeutic strategies.

Authors:  M A Magiakou; G P Chrousos
Journal:  J Endocrinol Invest       Date:  2002-02       Impact factor: 4.256

2.  Adrenal suppression by oral high-dose medroxyprogesterone acetate in breast cancer patients.

Authors:  H van Veelen; P H Willemse; D T Sleijfer; J J Pratt; W J Sluiter; H Doorenbos
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

3.  Mechanism of adrenal suppression by high-dose medroxyprogesterone acetate in breast cancer patients.

Authors:  H van Veelen; P H Willemse; D T Sleijfer; E van der Ploeg; W J Sluiter; H Doorenbos
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.